Nilotinib (AMN-107)

For research use only. Not for use in humans.

目录号:S1033 中文名称:尼洛替尼

Nilotinib (AMN-107) Chemical Structure

CAS No. 641571-10-0

Nilotinib (AMN-107)是一种特异性BCR-ABL抑制剂,在小鼠骨髓祖细胞中IC50低于30 nM。Nilotinib (AMN-107)可通过激活AMPK来诱导自噬。

规格 价格 库存 购买数量  
RMB 579.78 现货
RMB 1040.13 现货
RMB 1720.01 现货
RMB 3005.73 现货
RMB 3864.35 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Nilotinib (AMN-107)发表文献93篇:

产品安全说明书

Bcr-Abl抑制剂选择性比较

生物活性

产品描述 Nilotinib (AMN-107)是一种特异性BCR-ABL抑制剂,在小鼠骨髓祖细胞中IC50低于30 nM。Nilotinib (AMN-107)可通过激活AMPK来诱导自噬。
特性 Nilotinib 是Abl选择性抑制剂,与BCR-ABL的ATP结合位点相互作用。
靶点
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
体外研究

Nilotinib 作用于激活的HSCs,抑制增殖,迁移,和肌动蛋白形成,及 α-SMA和胶原的表达。Nilotinib 诱导HSCs凋亡,与bcl-2 表达降低相关,且提高p53 表达, PARP分裂,以及提高 PPARγ 和TRAIL-R表达。Nilotinib 也诱导细胞周期停滞,伴随着p27 的表达和cyclin D1的下调提高。Nilotinib 不仅抑制PDGFR的激活,也 通过Src抑制TGFRII。Nilotinib 显著抑制PDGF和 TGFβ刺激的ERK 和Akt磷酸化。而且, Nilotinib作用于人HSCs,抑制PDGF和TGFβ-激活的Abl磷酸化形式。 [2]Nilotinib抑制最抗 Imatinib的BCR-ABL突变,除了T315I。[3] Nilotinib 抑制PDGF-DD调节的 ERK1/2激活,基本的和PDGF-DD调节的 PDGFR-β和AKT激活,及schwannoma细胞增殖。 Nilotinib 比Imatinib更有效,发挥其最大抑制效果时的浓度比稳态血浆水平还低。[4] Nilotinib也显著降低TGF-β1和血小板衍生的生长因子(PDGF)基因表达水平。Nilotinib处理也显著抑制PDGF诱导的肺纤维细胞增殖。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M{nlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jJPWlEPTB;MD6wNFAyPDRizszN NFLMbpFUSU6JRWK=
KU812 NV\lPFF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHkTlh3UUN3ME2wMlAxOjR6IN88US=> NHLsSYNUSU6JRWK=
EM-2 NUTzXZJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7hcWd[UUN3ME2wMlAxPDFizszN M4LueHNCVkeHUh?=
LAMA-84 NGLRZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vKT2lEPTB;MD6wNFQ6KM7:TR?= M{HSRXNCVkeHUh?=
MEG-01 MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrEcIZKSzVyPUCuNFA5OjhizszN NVjYNpg5W0GQR1XS
BV-173 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3zTWM2OD1yLkCxNFg6KM7:TR?= MoCzV2FPT0WU
KASUMI-1 NVjvcnhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTvV49KSzVyPUCuNFI1OTNizszN MXzTRW5ITVJ?
NB7 NYq3XVFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHibWcxUUN3ME2wMlE{PDN7IN88US=> NVjiUZhGW0GQR1XS
BHT-101 NXT3b4NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPlXXBKSzVyPUCuOlQzPjNizszN NFzmOVhUSU6JRWK=
CGTH-W-1 NWnwRpFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLiTWM2OD1yLk[0PFch|ryP MUnTRW5ITVJ?
HMV-II M2D3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XQR2lEPTB;MD63OFg4PCEQvF2= NEOz[HJUSU6JRWK=
NKM-1 NXSwVWtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmzXVJKSzVyPUCuPVAyPSEQvF2= NGHxNYdUSU6JRWK=
LB2241-RCC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfDVYllUUN3ME2xMlAzOjJ6IN88US=> NILvOFFUSU6JRWK=
NCI-H1703 MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TYVmlEPTB;MT6xPFg4KM7:TR?= NWTwUnZrW0GQR1XS
BE-13 NGfiTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFwMke0NVYh|ryP NHjscXhUSU6JRWK=
ACN NGficphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFwNUWwO|ch|ryP NVXCOnRMW0GQR1XS
A204 NFroPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rHWWlEPTB;MT61O|IxPSEQvF2= Mn\CV2FPT0WU
HOP-62 M2fU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfITWM2OD1zLkiyNFc4KM7:TR?= NX36eWwzW0GQR1XS
H9 MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJwN{O3PVMh|ryP M2rQcXNCVkeHUh?=
HCC1806 M1PY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwN{SzNlch|ryP M1vjbHNCVkeHUh?=
NOS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG2WId[UUN3ME2yMlg4OTB{IN88US=> MlrKV2FPT0WU
RS4-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonrTWM2OD1{LkmwOlI{KM7:TR?= NEDDXI9USU6JRWK=
JAR NEXsOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jBeGlEPTB;Mj65NlA5PCEQvF2= M2rOV3NCVkeHUh?=
T98G NI\GeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTNwMEGzNVMh|ryP NIOyO4tUSU6JRWK=
NCI-SNU-1 NYnPOGhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T1UWlEPTB;Mz60NFA6OiEQvF2= NIrZU2dUSU6JRWK=
SK-MEL-1 NH;mTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XPW2lEPTB;Mz60N|AzQSEQvF2= MofMV2FPT0WU
L-363 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPUTWM2OD1|Lk[xNVA4KM7:TR?= Mlr5V2FPT0WU
SW982 M2D1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW2TWM2OD1|Lk[0NVY6KM7:TR?= M3HPfnNCVkeHUh?=
HT-1080 NVO2WFJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwOUG3O|Uh|ryP NFTnTGVUSU6JRWK=
G-402 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG0TWM2OD12LkOxNlA{KM7:TR?= M3;x[HNCVkeHUh?=
HOS NGiyNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRwOECyPFIh|ryP MkLLV2FPT0WU
SK-NEP-1 NGTWNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLaOZBKSzVyPUSuPFMyQTFizszN MnTDV2FPT0WU
HAL-01 NV7RcphoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnNbXNjUUN3ME20Mlg5OjR{IN88US=> M2nsbnNCVkeHUh?=
SBC-1 NWC0OY9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjMO|VOUUN3ME20MlkxQTB5IN88US=> Mnr4V2FPT0WU
CTV-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;4TWM2OD13LkS4PVM5KM7:TR?= NVTOdGpPW0GQR1XS
LCLC-103H MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XudWlEPTB;NT63O|Q4OSEQvF2= NH;QdIhUSU6JRWK=
RVH-421 Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTVwN{e1N|Yh|ryP NEj4b2hUSU6JRWK=
K-562 NY\xfGpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLqbpBKSzVyPUWuPVA{PiEQvF2= NHrvTFdUSU6JRWK=
CAL-33 M2r5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz6TWM2OD14LkOxN|U6KM7:TR?= NIP6bVZUSU6JRWK=
MDA-MB-361 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;lU|FKSzVyPU[uN|M3QTlizszN NWXIem52W0GQR1XS
IGROV-1 M4\nRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPzTWM2OD14LkS3NVkyKM7:TR?= NELyfldUSU6JRWK=
NY NIDhc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfRTWM2OD14LkWzOVk6KM7:TR?= M2jxVnNCVkeHUh?=
Ramos-2G6-4C10 M{TSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPITWM2OD14Lk[2PVMyKM7:TR?= NFXUR|VUSU6JRWK=
HuO9 NWjxNYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHOcGxKSzVyPU[uO|M6PjRizszN M1;HOnNCVkeHUh?=
MS-1 NFu2OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTaNZJKSzVyPUeuNVE6PTNizszN NYLS[GU3W0GQR1XS
RPMI-8226 NF61[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPudZI5UUN3ME23MlI5Ojh5IN88US=> NF[yfoFUSU6JRWK=
HDLM-2 NE\vbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTdwNECxOFkh|ryP NXTlN41tW0GQR1XS
D-566MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn2TWM2OD15LkS3NVU2KM7:TR?= NILYN2dUSU6JRWK=
SK-MEL-24 NEP3elZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf4TW1KSzVyPUeuOlM{QTJizszN MnfNV2FPT0WU
COLO-679 NXfqSJM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;uRoJ6UUN3ME23Mlk5PjdzIN88US=> NX3LNlZbW0GQR1XS
EW-13 NX;YTYQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRThwM{KwOVQh|ryP MmTLV2FPT0WU
A388 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zwVmlEPTB;OD6zPFQ5OSEQvF2= M{TNeXNCVkeHUh?=
UM-UC-3 M2PRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonFTWM2OD16LkSzPVU3KM7:TR?= MWfTRW5ITVJ?
NUGC-3 NYrRUFVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LDemlEPTB;OD61N|U5OiEQvF2= MnHmV2FPT0WU
COLO-668 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\ZSoxZUUN3ME24MlU6PDlzIN88US=> NET3TnBUSU6JRWK=
MOLT-4 NIjYRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRThwNkKzOVMh|ryP M{D3PXNCVkeHUh?=
D-423MG NV;SUVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HHXWlEPTB;OD64N|c2PiEQvF2= M3LoTnNCVkeHUh?=
CTB-1 NIGzdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPWXGlqUUN3ME24Mlg4OTJ6IN88US=> M2HQbnNCVkeHUh?=
BCPAP MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTlwMEK1OlIh|ryP NFPoTpNUSU6JRWK=
GCT M37lRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTlwMEm4N|Eh|ryP NVTHOlF1W0GQR1XS
ACHN M{K2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPSTWM2OD17LkKzOlMzKM7:TR?= NEjuUZpUSU6JRWK=
KYSE-520 MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjSWmpTUUN3ME25MlM{PDh{IN88US=> MknwV2FPT0WU
LB771-HNC NFrFVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\Jd2lEPTB;OT63OlQ6PyEQvF2= NUfGbHpzW0GQR1XS
MLMA NIfrO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFyLkCxN|Ih|ryP MXTTRW5ITVJ?
HEC-1 M4\OWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PNVWlEPTB;MUCuNlgxPCEQvF2= NELpV4pUSU6JRWK=
HL-60 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFyLk[4OVMh|ryP NXn4dWc6W0GQR1XS
A101D NGrMU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr1SGI2UUN3ME2xNE45QTJ|IN88US=> MVnTRW5ITVJ?
A2058 M2TvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;0TWM2OD1zMD65NlQ2KM7:TR?= NGS3VY9USU6JRWK=
KARPAS-45 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ThbmlEPTB;MUGuNFY{PSEQvF2= MVLTRW5ITVJ?
697 NV\senV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDxTm42UUN3ME2xNU4zOTBzIN88US=> NWTzPVR4W0GQR1XS
NCI-N87 NWf3eZVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fCemlEPTB;MUGuO|c{OSEQvF2= MnzaV2FPT0WU
DSH1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPjTWM2OD1zMT63PVU{KM7:TR?= NXPXXmtkW0GQR1XS
HLE MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXtTWM2OD1zMT64PFM6KM7:TR?= MXzTRW5ITVJ?
NCI-H720 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fmSGlEPTB;MUKuOlgxOSEQvF2= NIDvOm1USU6JRWK=
EW-3 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz1VlZKSzVyPUGyMlk{ODdizszN M1XVUXNCVkeHUh?=
AGS M3;2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37sfmlEPTB;MUOuNFM2OSEQvF2= NF\iNnZUSU6JRWK=
ES5 NWrWcG1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF|LkC1NVIh|ryP NVrsfFZLW0GQR1XS
DB NGfQT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\4c2lEPTB;MUOuN|I2PiEQvF2= NHfacYRUSU6JRWK=
A4-Fuk MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS0TWM2OD1zMz60NVAzKM7:TR?= NIq0eYpUSU6JRWK=
A427 M3zxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jBS2lEPTB;MUOuOFk4OiEQvF2= NGrpR5VUSU6JRWK=
MN-60 MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF|LkW4OFMh|ryP M2PPWHNCVkeHUh?=
HCC2218 M1PWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LDXGlEPTB;MUOuOVg2PiEQvF2= NGLnfHNUSU6JRWK=
MV-4-11 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF|LkixN|ch|ryP M3W3c3NCVkeHUh?=
GI-1 MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF2LkGxPFQh|ryP M4nqe3NCVkeHUh?=
JVM-3 M1rn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\6WmVKSzVyPUG0MlI3PTZizszN M2PhWnNCVkeHUh?=
NCI-H2029 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H4XmlEPTB;MUSuNlczPyEQvF2= NXWyZ4NOW0GQR1XS
TE-12 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPyOnFKSzVyPUG0MlYxPDZizszN NY\TUWI{W0GQR1XS
WM-115 NXnRR2NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjW[mp1UUN3ME2xOU42Pjh|IN88US=> M2qzSHNCVkeHUh?=
BB65-RCC NWDLU21kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\hR2lEPTB;MU[uNFI1OSEQvF2= MV7TRW5ITVJ?
NCI-H1693 NHHCTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\xSW1bUUN3ME2xOk4{QDB{IN88US=> NGDtd2JUSU6JRWK=
KARPAS-299 NHvITYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLrTWM2OD1zNj62NlA{KM7:TR?= M2PHS3NCVkeHUh?=
UACC-257 NIr1fJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDwNnRKSzVyPUG3MlA2QDJizszN NVXSZ|M2W0GQR1XS
RKO MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTF5Lk[0N|Mh|ryP M1LIVnNCVkeHUh?=
HT-29 M{KxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT5Wo9KSzVyPUG3Mlc5QDlizszN NEfBdpNUSU6JRWK=
ES7 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fyRmlEPTB;MUiuNVEzOiEQvF2= MX\TRW5ITVJ?
DEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\DTWM2OD1zOD6zNVczKM7:TR?= NV;DSpYzW0GQR1XS
BT-549 M4\BfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTZTWM2OD1zOD60NFkzKM7:TR?= NGG0Xo1USU6JRWK=
NCI-H1755 M1uxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTKTWM2OD1zOD61O|I{KM7:TR?= NYTMe4gzW0GQR1XS
HCE-T M2DXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfyflBKSzVyPUG4Mlg{PDFizszN MnK0V2FPT0WU
LU-139 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HNfGlEPTB;MUmuNFQ2QCEQvF2= M165VnNCVkeHUh?=
ECC10 NG[0flBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXCSXpoUUN3ME2xPU4zPDd3IN88US=> MmjNV2FPT0WU
769-P MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXSweplnUUN3ME2xPU43OzN3IN88US=> MYXTRW5ITVJ?
BALL-1 NIrEZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF7Lk[3O|Uh|ryP MVXTRW5ITVJ?
LXF-289 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jrTmlEPTB;MUmuPFk4QSEQvF2= MknyV2FPT0WU
TYK-nu M4H2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF7LkmzNVUh|ryP MmnXV2FPT0WU
NCI-H630 NFXaUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jYPGlEPTB;MUmuPVM4QCEQvF2= MlHOV2FPT0WU
EW-18 NGf6XGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\PZWlEPTB;MkCuN|gxOiEQvF2= MWLTRW5ITVJ?
KYSE-150 M1WwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnQUplKSzVyPUKwMlcxPDdizszN NYDwZWxjW0GQR1XS
LOXIMVI MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\jWGlEPTB;MkCuO|U5PiEQvF2= NHjuWIxUSU6JRWK=
HuP-T3 NHHTTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT6WXdKSzVyPUKxMlA5PTJizszN NFLpXHhUSU6JRWK=
MFE-280 MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M172cWlEPTB;MkGuOVY4QSEQvF2= M1\WcXNCVkeHUh?=
SK-OV-3 NXq4NVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nBbmlEPTB;MkGuPFQxQCEQvF2= MYfTRW5ITVJ?
QIMR-WIL Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ{LkC0O|gh|ryP Mn2zV2FPT0WU
NCI-H69 NHTsWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LITGlEPTB;MkKuOFI6QSEQvF2= Ml3vV2FPT0WU
TE-5 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;FZoNKSzVyPUKyMlQ6PjVizszN M3POR3NCVkeHUh?=
NCI-H1993 NHrQS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfNWYVKSzVyPUKyMlQ6PzFizszN MWXTRW5ITVJ?
NCI-H1092 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;P[2lEPTB;MkOuNlg1OyEQvF2= NHPpOHZUSU6JRWK=
RH-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILoc4RKSzVyPUKzMlU{PTdizszN M3z0eXNCVkeHUh?=
DBTRG-05MG M3HQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm4[otKSzVyPUKzMlg1PzJizszN MWnTRW5ITVJ?
Mo-T M2ezOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJ|Lkmg{txO M{f4OnNCVkeHUh?=
HD-MY-Z MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ2LkKzOlIh|ryP NVuzXVN1W0GQR1XS
NCI-H2342 M1LCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH4TWM2OD1{ND62O|Y4KM7:TR?= NEHpfo5USU6JRWK=
C32 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DMSGlEPTB;MkSuPVU4PiEQvF2= NV;FbXJ1W0GQR1XS
HTC-C3 NHTTXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlKwTWM2OD1{NT6zOVc4KM7:TR?= MnznV2FPT0WU
NCI-H358 M3vTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\0TWM2OD1{NT6zPVQ{KM7:TR?= NXnTbnVIW0GQR1XS
CAL-85-1 NHrWfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULX[4FnUUN3ME2yOU41PTd5IN88US=> MY\TRW5ITVJ?
HT-1197 M1vhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJ3LkWzNVkh|ryP MY\TRW5ITVJ?
A172 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ3LkexN|Yh|ryP NILxRWVUSU6JRWK=
SW1573 MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LXbmlEPTB;MkWuO|c5PSEQvF2= MnTTV2FPT0WU
EW-24 M3vUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ3Lkm2NkDPxE1? NIm4RVZUSU6JRWK=
SK-MEL-2 NYjkXmdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJ4LkCzNVIh|ryP NYHnNopNW0GQR1XS
LU-65 M1S3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PCfWlEPTB;Mk[uNFQ2OiEQvF2= NIrOVWRUSU6JRWK=
KMOE-2 M33Mdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHkTWM2OD1{Nj6wPVE2KM7:TR?= MUjTRW5ITVJ?
H-EMC-SS M4P1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke3TWM2OD1{Nj60NVE1KM7:TR?= NFfGWYdUSU6JRWK=
H4 M3TuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli4TWM2OD1{Nj60NlQ{KM7:TR?= NUPmW5R{W0GQR1XS
DU-4475 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ5LkG4O|Ih|ryP NV;iSppQW0GQR1XS
HCT-116 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\uOmlEPTB;MkeuOFM1QSEQvF2= NIS4SpJUSU6JRWK=
MSTO-211H NFG4b3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG0TWM2OD1{Nz62NlU2KM7:TR?= Mo\hV2FPT0WU
NCI-H292 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm4e|ZKSzVyPUK3Mlk3OTdizszN MnnJV2FPT0WU
NCI-H446 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWzTWM2OD1{OD6yNVA2KM7:TR?= NVuxN5N4W0GQR1XS
NCI-H2009 M1PNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1noemlEPTB;MkmuNVQ{OSEQvF2= NXTBfZFJW0GQR1XS
MHH-ES-1 M{Wwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ7LkO2PFUh|ryP NYjPUIVKW0GQR1XS
TI-73 NY\VNpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\BeWpwUUN3ME2yPU41ODBzIN88US=> M1vaVHNCVkeHUh?=
NCI-H2228 NXGxO5BqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ7LkS1PEDPxE1? MX\TRW5ITVJ?
MHH-PREB-1 M2HQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLlTWM2OD1{OT61OVA2KM7:TR?= M1nCXnNCVkeHUh?=
ChaGo-K-1 M4XXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTOTWM2OD1{OT62NFk4KM7:TR?= MUPTRW5ITVJ?
KY821 NFjBZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL0TWM2OD1{OT62OFM{KM7:TR?= NHzaSlZUSU6JRWK=
NCI-H209 M3;MVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHwR|VKSzVyPUK5Mlg{PjZizszN MmDZV2FPT0WU
NBsusSR MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jQeGlEPTB;MkmuPVkxPCEQvF2= MXrTRW5ITVJ?
NCI-H1304 M4qyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rRV2lEPTB;M{CuOVcyPiEQvF2= NVvuVXUyW0GQR1XS
NB14 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTNzLkC0OFYh|ryP NV7SZ|VlW0GQR1XS
HCC1419 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNzLkK0JO69VQ>? NWOxT5A6W0GQR1XS
KG-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTsTWM2OD1|MT63OFI6KM7:TR?= NGXWOWtUSU6JRWK=
A2780 M{jHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H0OmlEPTB;M{GuPFM2QCEQvF2= NIryN3NUSU6JRWK=
NCI-H28 NHS4e45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnezTWM2OD1|MT65PFYyKM7:TR?= MoDpV2FPT0WU
C2BBe1 MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jJbWlEPTB;M{KuNlY{PCEQvF2= MUDTRW5ITVJ?
VA-ES-BJ NYrreoI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz4cWZKSzVyPUOyMlMyKM7:TR?= MXLTRW5ITVJ?
SBC-5 M2PKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\jcZd6UUN3ME2zNk45PTFzIN88US=> NWLFW3NwW0GQR1XS
OVCAR-4 M4juWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7V[YRRUUN3ME2zN{41QDR6IN88US=> NIKyVoZUSU6JRWK=
COR-L88 NHzlZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTN2LkC3OFEh|ryP MUnTRW5ITVJ?
SW954 NFv3[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\STWM2OD1|ND6wO|UzKM7:TR?= NVTpXlIxW0GQR1XS
COLO-684 NXzhZXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXzXGREUUN3ME2zOE4{PDB2IN88US=> NGf5N4xUSU6JRWK=
HCC70 NH3GVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN2Lkm1NVQh|ryP MnrWV2FPT0WU
NCI-H1770 NWTmeHk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:0fIloUUN3ME2zOE46PjFizszN NHjtOmhUSU6JRWK=
NCI-H1666 NYPKc5p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTN3LkiyOVMh|ryP Ml;VV2FPT0WU
YH-13 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO4TWM2OD1|NT65NkDPxE1? M1PsRnNCVkeHUh?=
DJM-1 NIHEbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XMSmlEPTB;M{[uPFA1QSEQvF2= Mki4V2FPT0WU
KNS-62 NV3IUIdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULpSY1VUUN3ME2zOk46PDN6IN88US=> NEHtV4xUSU6JRWK=
SK-MEL-30 NVjFO|JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml30TWM2OD1|Nz64O|M4KM7:TR?= MWTTRW5ITVJ?
SJRH30 NFXmfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPDSIRWUUN3ME2zPE44OzRzIN88US=> M{fxT3NCVkeHUh?=
GP5d NYTkeHhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr5WYVKSzVyPUO4Mlg3PTNizszN MV;TRW5ITVJ?
SW1116 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF22T2hKSzVyPUO5MlI5ODVizszN NUXye|I4W0GQR1XS
COLO-800 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn1[FV2UUN3ME2zPU4{PjN6IN88US=> M{f2NnNCVkeHUh?=
RD M{HPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHVXm5mUUN3ME2zPU42OjV6IN88US=> M2HMbHNCVkeHUh?=
NCI-SNU-5 NFXHO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC2TWM2OD1|OT62PVE3KM7:TR?= NUjoO4o4W0GQR1XS
HuO-3N1 M1HlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTRyLkGwPEDPxE1? MX\TRW5ITVJ?
SK-UT-1 M37MWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G4SWlEPTB;NECuOVY4PCEQvF2= MXjTRW5ITVJ?
SK-MEL-3 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPlNVVKSzVyPUSwMlU6OzJizszN NY\Wb452W0GQR1XS
SK-MEL-28 MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DTZmlEPTB;NECuOlQ{PSEQvF2= NVrGZlBFW0GQR1XS
SCC-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTRzLkKxN|ch|ryP M{D1TnNCVkeHUh?=
no-11 NXfLXIFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXUTWM2OD12MT63N|U1KM7:TR?= NFf3S4NUSU6JRWK=
HT-144 NF7sRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTR{LkC1Olch|ryP M3TxOHNCVkeHUh?=
MFM-223 M3uzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\aNmlEPTB;NEKuOFAzKM7:TR?= M{PPdnNCVkeHUh?=
ONS-76 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\DeGlEPTB;NEKuPFAyQCEQvF2= MUDTRW5ITVJ?
ES8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XmUmlEPTB;NEOuN|Y6QCEQvF2= MmPUV2FPT0WU
T-24 NFrXU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfyOJFnUUN3ME20N{41OzZ7IN88US=> MmX0V2FPT0WU
GAMG Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTR|LkS1NVch|ryP Mle0V2FPT0WU
LU-135 Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTzTWM2OD12ND6wPVI{KM7:TR?= NXPBZ2NrW0GQR1XS
HCC1187 NULWc2dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PCUGlEPTB;NESuPFI3OiEQvF2= MmS4V2FPT0WU
TE-1 NF\KVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDpTWM2OD12NT6xOlU1KM7:TR?= NELFU3JUSU6JRWK=
J-RT3-T3-5 NVH2bVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrUTWM2OD12NT60N|E2KM7:TR?= MWPTRW5ITVJ?
GI-ME-N MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHac2ROUUN3ME20OU45QTV{IN88US=> NFr6WYNUSU6JRWK=
D-392MG NYfL[ZJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYraSJVuUUN3ME20OU46OjV4IN88US=> MUTTRW5ITVJ?
KALS-1 M4jnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTR4LkeyOVch|ryP M{L5fHNCVkeHUh?=
MMAC-SF M2XqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTR4Lkm5OVIh|ryP MXLTRW5ITVJ?
HSC-3 M1nGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;ReWlEPTB;NEeuN|YxQCEQvF2= NI[1Z2NUSU6JRWK=
KM-H2 M3\F[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nJXmlEPTB;NEeuOlAxPyEQvF2= NX;FboxUW0GQR1XS
LoVo M4LzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrmfohKSzVyPUS4MlExODJizszN NUfu[W94W0GQR1XS
NCI-H510A MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTR6LkG4O|Eh|ryP M1X6bnNCVkeHUh?=
EW-11 Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTR6LkKzOFgh|ryP M1;UNnNCVkeHUh?=
HCC2998 NUnOO21TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nNbGlEPTB;NEiuOlI{PiEQvF2= NHvtXWxUSU6JRWK=
J82 NYmy[WNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH0TWM2OD12OD63NlQzKM7:TR?= NXfWRoJRW0GQR1XS
ML-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfBTWM2OD12OT60OlA2KM7:TR?= MXLTRW5ITVJ?
NCI-H2030 NEjqNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfN[lBKSzVyPUS5MlcyOTdizszN MUHTRW5ITVJ?
NCI-H1792 NXrPfYpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR7Lki1NVgh|ryP NGPWeXlUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AMPKα / AMPKα / p-AMPKβ1 / AMPKγ2 / p-LKB1 / LKB1 / CaMKIIβ ; 

PubMed: 23677989     


Dose-dependent analysis of AMPK-related molecules in HCC cells. Cells were exposed to nilotinib at the indicated concentrations for 24 h.

DNMT1 / DNMT3a / DNMT3b ; 

PubMed: 28720666     


Kasumi-1 or MV4-11 cells were treated for 24 h with the indicated doses of nilotinib and subjected western blot analysis to detect the expression levels of DNMT1, DNMT3a, DNMT3b.

pABL1 / p-NF-κB1 / NF-κB / STAT3 / p-STAT3 / IL-1β / IL-6 / COX2 ; 

PubMed: 31396300     


ABL1 regulated the inflammation signaling pathway. Blocking activities of ABL1 with Imatinib and Nilotinib inhibits the inflammatory signaling pathway including activities of NF-κB1, STAT3, IL-1β, IL-6, and COX2.

23677989 28720666 31396300
Growth inhibition assay
Cell viability; 

PubMed: 23677989     


Dose-dependent effects of nilotinib on cell viability. HCC cells were treated with nilotinib at the indicated concentrations for 72 h. Cell viability was measured by MTT assay. Points, mean; bars, S.D. (n = 8). 

23677989
体内研究 Nilotinib 作用于CCl4和BDL诱导的纤维化,降低胶原沉积和α-SMA表达。 Nilotinib 可以诱导HSC发生凋亡,与bcl-2的下调相关。 [2] Nilotinib轻肺损伤和纤维化程度。Nilotinib 疗法在第14天和21天,显著降低羟脯氨酸水平 ,伴随着转化生长因子(TGF)-β1和 PDGFR-β表达水平降低。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[4]
- 合并
  • Cell lines: 人类原代Schwann 和schwannoma细胞
  • Concentrations: 1 μM -10 μM
  • Incubation Time: 72小时
  • Method: 人类原代 Schwann和 schwannoma细胞接种在预包被的96孔板上。加入Nilotinib,40分钟后,使用100 ng/mL PDGF-DD刺激处理,细胞培养72小时(3 天)。因为Nilotinib的半衰期为18小时, 每天新鲜补充的浓度为最初加入浓度的一半。除了DAPI染色和测定全部细胞数外, 使用更敏感和准确的 BrdU渗透法测定增殖细胞。 使用倒置荧光显微镜和200 ×放大倍率。计算全部细胞数(DAPI)和分裂细胞数(BrdU阳性)。计数每孔中的所有细胞。每孔中不同批次细胞的全部细胞数不同。
    (Only for Reference)
动物实验:[4]
- 合并
  • Animal Models: 雄性6周大的C57BL6小鼠
  • Dosages: 100 mg/kg
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 27 mg/mL (50.98 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 529.52
化学式

C28H22F3N7O

CAS号 641571-10-0
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04326933 Not yet recruiting Drug: Tyrosine kinase Inhibitors (Imatinib & Nilotinib) Patients Diagnosed as Chronic Meyloid Leukemia Assiut University October 20 2020 --
NCT03942094 Recruiting Drug: Nilotinib Chronic Myeloid Leukemia Chronic Phase|Nilotinib Shenzhen Second People''s Hospital June 1 2019 Phase 3
NCT03874858 Recruiting Drug: Nilotinib Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 1 2019 Phase 2
NCT04002674 Recruiting Drug: Placebo oral capsule|Drug: Nilotinib Oral Capsule Dementia With Lewy Bodies Georgetown University|National Institutes of Health (NIH) January 14 2019 Phase 2
NCT02973711 Suspended Drug: Nilotinib|Drug: Ruxolitinib Leukemia Chronic Myeloid University of Michigan Rogel Cancer Center January 18 2018 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to use AMN-107 for in vivo studies in mice, can you give me some suggestions about the in vivo formulation?

  • 回答:

    For in vivo study, we recommend to use 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 3mg/ml.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

相关Bcr-Abl产品

Tags: 购买Nilotinib (AMN-107) | Nilotinib (AMN-107)供应商 | 采购Nilotinib (AMN-107) | Nilotinib (AMN-107)价格 | Nilotinib (AMN-107)生产 | 订购Nilotinib (AMN-107) | Nilotinib (AMN-107)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID